Wells Fargo analyst Brandon Couillard initiated coverage of Bio-Techne (TECH) with an Overweight rating and $59 price target The firm believes Bio-Techne’s “unique” portfolio is well positioned to deliver sustained above-average organic revenue and earnings growth. The company is exposed to high-growth verticals, such as good manufacturing practice reagents, proteomic instruments, spatial biology and precision diagnostics, the analyst tells investors in a research note. Wells believes the recent pullback in the shares offers a compelling entry point.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue